http://www.intercell.com/main/forinvestors/downloads/annual-reports/

In our current Annual Report, we provide you with an outline of the developments at Intercell AG in 2011:

  • Significant increase of IXIARO®/JESPECT® sales by 68% to EUR 21.6m, reflecting the significant potential of our first product on the market
  • Intercell's prioritized R&D pipeline programs with a focus on a capital-efficient and diversified portfolio - ppromising vaccine candidates out of our research pipeline are progressing to the next value inflection points
  • The execution of Intercell's renewal strategy including significant cost cutting, re-structuring measures and consolidating R&D activities

Our Annual Report provides information on our activities, and results in 2011 while giving you an outlook on the 2012 fiscal year.

distributed by